{"id":18185,"date":"2020-10-12T18:34:22","date_gmt":"2020-10-12T16:34:22","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=18185"},"modified":"2020-10-12T18:34:22","modified_gmt":"2020-10-12T16:34:22","slug":"fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/","title":{"rendered":"FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Glycostem announces it has received the FDA\u2019s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord<sup>\u00ae<\/sup>. The designation will provide Glycostem with certain incentives, like eligibility for 7 years of market exclusivity and clear FDA guidance on specific aspects of development for rare diseases. These pave an accelerated path towards market access and treatment of patients suffering from this relatively rare form of cancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">oNKord\u00aeis Glycostem\u2019s first-generation off-the-shelf Natural Killer (NK) cellular immunotherapy product. Over the coming months, AML patients will receive this form of treatment as part of a phase I-IIa (pivotal) trial in AML. A phase II trial for MM patients isexpected to start in 2021. This makes Glycostem one of the frontrunners in this promising field of cellular immunotherapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cSince 2012 we have been pioneers in the field of developing and manufacturing off-the-shelf Natural Killer cell therapy products for cancer treatment. In 2020 we\u2019re entering a new and exciting phase,\u201d says Troels Jordansen, CEO of Glycostem. \u201cIt is great to experience that after receiving FDA and EMA ODD designation for AML, the FDA has also granted us this designation for MM. This allows us to accelerate oNKord\u00ae\u2019s access to the US market and our ultimate ambition: curing cancer.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MM is the second most common blood cancer, accounting for 15% of blood cancers, and 2% of all cancers. In the US alone it affects more than 130,000 patients; approximately 32,000 Americans are diagnosed with MM each year. MM occurs in infection-fighting plasma cells (a type of white blood cell) found in the bone marrow. These cancerous cells multiply, produce an abnormal protein and push out other healthy blood cells from the bone marrow.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Source: Glycostem (<a href=\"https:\/\/glycostem.com\/news\/fda-grants-glycostems-onkordr-orphan-drug-designation-multiple-myeloma\">Press release<\/a>)<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glycostem announces it has received the FDA\u2019s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord\u00ae. The designation will provide Glycostem with certain incentives, like eligibility for 7 years of market exclusivity and clear FDA guidance on specific aspects of development for rare diseases. These pave an accelerated [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[39],"tags":[],"class_list":["post-18185","post","type-post","status-publish","format-standard","hentry","category-gezondheid"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma - hollandbio\" \/>\n<meta property=\"og:description\" content=\"Glycostem announces it has received the FDA\u2019s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord\u00ae. The designation will provide Glycostem with certain incentives, like eligibility for 7 years of market exclusivity and clear FDA guidance on specific aspects of development for rare diseases. These pave an accelerated [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-12T16:34:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"HollandBIO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"HollandBIO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\\\/\"},\"author\":{\"name\":\"HollandBIO\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\"},\"headline\":\"FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma\",\"datePublished\":\"2020-10-12T16:34:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\\\/\"},\"wordCount\":294,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Gezondheid\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\\\/\",\"name\":\"FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2020-10-12T16:34:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\",\"name\":\"HollandBIO\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/","og_locale":"en_US","og_type":"article","og_title":"FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma - hollandbio","og_description":"Glycostem announces it has received the FDA\u2019s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord\u00ae. The designation will provide Glycostem with certain incentives, like eligibility for 7 years of market exclusivity and clear FDA guidance on specific aspects of development for rare diseases. These pave an accelerated [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/","og_site_name":"hollandbio","article_published_time":"2020-10-12T16:34:22+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"HollandBIO","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"HollandBIO","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/"},"author":{"name":"HollandBIO","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea"},"headline":"FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma","datePublished":"2020-10-12T16:34:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/"},"wordCount":294,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Gezondheid"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/","name":"FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2020-10-12T16:34:22+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-grants-glycostems-onkord-orphan-drug-designation-for-multiple-myeloma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"FDA grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea","name":"HollandBIO"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/18185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=18185"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/18185\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=18185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=18185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=18185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}